INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

RCUSArcus Biosciences, Inc.

CIK 0001724521

EDGAR filingsOpen in network
Disclosed transactions20
Buys / sells0 / 8
Max Insider Score22
Connections6with evidence

RCUS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GC
Goeltz II Robert C.Chief Financial Officer
RCUSArcus Biosciences, Inc.
Grant or award
A—
96.0K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 5, 2026
  • ← Insider ofevidence
    Jarrett JenniferChief Operating Officer · Jan 26, 2026
  • ← Insider ofevidence
    Goeltz II Robert C.Chief Financial Officer · Jan 26, 2026
  • ← Insider ofevidence
    Markus RichardChief Medical Officer · Dec 18, 2025
13
MR
Markus RichardChief Medical Officer
RCUSArcus Biosciences, Inc.
Grant or award
A
—
24.0K sh
Jan 23, 2026
Jan 26, 2026
traded Jan 23, 2026
+3d
SEC FORM 4

Evidence

5
MR
Markus RichardChief Medical Officer
RCUSArcus Biosciences, Inc.
Grant or award
A—
96.0K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

9
TC
Tang Carolyn C.General Counsel
RCUSArcus Biosciences, Inc.
Grant or award
A—
24.0K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

5
TC
Tang Carolyn C.General Counsel
RCUSArcus Biosciences, Inc.
Grant or award
A—
96.0K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

17
AA
Azoy AlexanderChief Accounting Officer
RCUSArcus Biosciences, Inc.
Grant or award
A—
21.1K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

5
AA
Azoy AlexanderChief Accounting Officer
RCUSArcus Biosciences, Inc.
Grant or award
A—
14.1K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

13
JJ
Jarrett JenniferChief Operating Officer
RCUSArcus Biosciences, Inc.
Grant or award
A—
31.0K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

9
JJ
Jarrett JenniferChief Operating Officer
RCUSArcus Biosciences, Inc.
Grant or award
A—
126.0K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

17
GC
Goeltz II Robert C.Chief Financial Officer
RCUSArcus Biosciences, Inc.
Grant or award
A—
24.0K sh
Jan 23, 2026Jan 26, 2026
traded Jan 23, 2026
+3dSEC FORM 4

Evidence

22
MR
Markus RichardChief Medical Officer
RCUSArcus Biosciences, Inc.
Open-market sale · 10b5-1 plan
SELL$111K
5,052 sh
Dec 16, 2025Dec 18, 2025
traded Dec 16, 2025
+2dSEC FORM 4

Evidence

18
MR
Markus RichardChief Medical Officer
RCUSArcus Biosciences, Inc.
Open-market sale · 10b5-1 plan
SELL$100K
4,494 sh
Dec 17, 2025Dec 18, 2025
traded Dec 17, 2025
+1dSEC FORM 4

Evidence

22
TC
Tang Carolyn C.General Counsel
RCUSArcus Biosciences, Inc.
Open-market sale · 10b5-1 plan
SELL$168K
7,658 sh
Dec 16, 2025Dec 18, 2025
traded Dec 16, 2025
+2dSEC FORM 4

Evidence

18
TC
Tang Carolyn C.General Counsel
RCUSArcus Biosciences, Inc.
Open-market sale · 10b5-1 plan
SELL$151K
6,810 sh
Dec 17, 2025Dec 18, 2025
traded Dec 17, 2025
+1dSEC FORM 4

Evidence

18
AA
Azoy AlexanderChief Accounting Officer
RCUSArcus Biosciences, Inc.
Open-market sale · 10b5-1 plan
SELL$52K
2,376 sh
Dec 16, 2025Dec 18, 2025
traded Dec 16, 2025
+2dSEC FORM 4

Evidence

15
AA
Azoy AlexanderChief Accounting Officer
RCUSArcus Biosciences, Inc.
Open-market sale · 10b5-1 plan
SELL$47K
2,113 sh
Dec 17, 2025Dec 18, 2025
traded Dec 17, 2025
+1dSEC FORM 4

Evidence

18
AA
Azoy AlexanderChief Accounting Officer
RCUSArcus Biosciences, Inc.
Open-market sale · 10b5-1 plan
SELL$97K
4,343 sh
Dec 18, 2025Dec 18, 2025
traded Dec 18, 2025
+0dSEC FORM 4

Evidence

9
AA
Azoy AlexanderChief Accounting Officer
RCUSArcus Biosciences, Inc.
Option exercise · 10b5-1 plan
M$25K
1,900 sh
Nov 26, 2025Dec 1, 2025
traded Nov 26, 2025
+5dSEC FORM 4

Evidence

15
AA
Azoy AlexanderChief Accounting Officer
RCUSArcus Biosciences, Inc.
Open-market sale · 10b5-1 plan
SELL$49K
1,900 sh
Nov 26, 2025Dec 1, 2025
traded Nov 26, 2025
+5dSEC FORM 4

Evidence

13
AA
Azoy AlexanderChief Accounting Officer
RCUSArcus Biosciences, Inc.
Option exercise · 10b5-1 plan
M—
1,900 sh
Nov 26, 2025Dec 1, 2025
traded Nov 26, 2025
+5dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Tang Carolyn C.General Counsel · Dec 18, 2025
  • ← Insider ofevidence
    Azoy AlexanderChief Accounting Officer · Dec 1, 2025